3-((tert-butoxycarbonyl)amino)-2-(4-(3-(2-chloro-3,6-difluorophenoxy)propyl)benzyl)propanoic acid | 1223461-40-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-((tert-butoxycarbonyl)amino)-2-(4-(3-(2-chloro-3,6-difluorophenoxy)propyl)benzyl)propanoic acid
• CAS: 1223461-40-2
• 化学式: C₂₄H₂₈ClF₂NO₅
• 分子量: 483.94
• InChiKey: HDBNUQOVPKCDEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  33.0
• 可旋转键数：
  10.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  84.86
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  cyclopropyl-(2,3-dichlorobenzyl)amine 、 3-((tert-butoxycarbonyl)amino)-2-(4-(3-(2-chloro-3,6-difluorophenoxy)propyl)benzyl)propanoic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 以75%的产率得到tert-butyl (2-(4-(3-(2-chloro-3,6-difluorophenoxy)propyl)benzyl)-3-(cyclopropyl(2,3-dichlorobenzyl)amino)-3-oxopropyl)carbamate
  参考文献：
  名称：

  Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension

  摘要：

  The discovery and SAR of a new series of substituted amino propanamide renin inhibitors are herein described. This work has led to the preparation of compounds with in vitro and in vivo profiles suitable for further development. Specifically, challenges pertaining to oral bioavailability, covalent binding and time-dependent CYP 3A4 inhibition were overcome thereby culminating in the identification of compound 50 as an optimized renin inhibitor with good efficacy in the hypertensive double-transgenic rat model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.036
• 作为产物：
  描述：

  在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 16.0h， 以99%的产率得到3-((tert-butoxycarbonyl)amino)-2-(4-(3-(2-chloro-3,6-difluorophenoxy)propyl)benzyl)propanoic acid
  参考文献：
  名称：

  Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension

  摘要：

  The discovery and SAR of a new series of substituted amino propanamide renin inhibitors are herein described. This work has led to the preparation of compounds with in vitro and in vivo profiles suitable for further development. Specifically, challenges pertaining to oral bioavailability, covalent binding and time-dependent CYP 3A4 inhibition were overcome thereby culminating in the identification of compound 50 as an optimized renin inhibitor with good efficacy in the hypertensive double-transgenic rat model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.036